Moleculin Biotech Launches Phase 1B/2 Trial of Annamycin for Advanced Pancreatic Cancer
Reuters
Oct 23, 2025
<a href="https://laohu8.com/S/MBRX">Moleculin Biotech</a> Launches Phase 1B/2 Trial of Annamycin for Advanced Pancreatic Cancer
Moleculin Biotech Inc. announced a new investigator-initiated Phase 1B/2 clinical study to evaluate Annamycin (naxtarubicin) as a third-line treatment for advanced pancreatic cancer. The study will be conducted by Atlantic Health inNew Jersey, with Moleculin supplying the investigational drug and overseeing the related FDA regulatory process. The estimated cost for the trial, including long-term follow-up through 2030, is approximately $1 million, primarily for drug supply and laboratory testing. Results from this study have not yet been presented. Separately, Moleculin is conducting a pivotal Phase 2B/3 global trial (the MIRACLE trial) of Annamycin in combination with cytarabine for adults with relapsed or refractory acute myeloid leukemia (AML). Further information about the MIRACLE trial is available under clinicaltrials.gov identifier NCT06788756.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-031574), on October 23, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.